Suppr超能文献

血管内腹主动脉瘤修复术的成本效益

Cost-effectiveness of endovascular abdominal aortic aneurysm repair.

作者信息

Michaels J A, Drury D, Thomas S M

机构信息

Academic Vascular Unit, Coleridge House, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK.

出版信息

Br J Surg. 2005 Aug;92(8):960-7. doi: 10.1002/bjs.5119.

Abstract

BACKGROUND

The rapid introduction of endovascular abdominal aortic aneurysm repair (EVAR) has considerable implications for the management of abdominal aortic aneurysm (AAA). This study was undertaken to determine an optimal strategy for the use of EVAR based on the best currently available evidence.

METHODS

Economic modelling and probabilistic sensitivity analysis considered reference cases representing a fit 70-year-old with a 5.5-cm diameter AAA (RC1) and an 80-year-old with a 6.5-cm AAA unfit for open surgery (RC2). Results were assessed as incremental cost-effectiveness ratio (ICER) compared with open repair (RC1) or conservative management (RC2).

RESULTS

In RC1 EVAR produced a gain of 0.10 quality-adjusted life years (QALYs) for an estimated cost of 11,449 pound, giving an ICER of 110,000 pound per QALY. EVAR consistently had an ICER above 30,000 pound per QALY over a range of sensitivity analyses and alternative scenarios. In RC2 EVAR produced an estimated benefit of 1.64 QALYs for an incremental cost of 14,077 pound giving an incremental cost per QALY of 8579 pound.

CONCLUSION

: It is unlikely that EVAR for fit patients suitable for open repair is within the commonly accepted range of cost-effectiveness for a new technology. For those unfit for conventional open repair it is likely to be a cost-effective alternative to non-operative management. Sensitivity analysis suggests that research efforts should concentrate on determining accurate rates for late complications and reintervention, particularly in patients with high operative risks.

摘要

背景

血管内腹主动脉瘤修复术(EVAR)的迅速引入对腹主动脉瘤(AAA)的治疗具有重大影响。本研究旨在根据目前可得的最佳证据确定EVAR的最佳使用策略。

方法

经济建模和概率敏感性分析考虑了代表一名适合手术的70岁、直径5.5厘米AAA患者(RC1)和一名不适合开放手术的80岁、直径6.5厘米AAA患者(RC2)的参考病例。结果以与开放修复(RC1)或保守治疗(RC2)相比的增量成本效益比(ICER)进行评估。

结果

在RC1中,EVAR产生了0.10个质量调整生命年(QALY)的收益,估计成本为11,449英镑,ICER为每QALY 110,000英镑。在一系列敏感性分析和替代方案中,EVAR的ICER始终高于每QALY 30,000英镑。在RC2中,EVAR产生了1.64个QALY的估计收益,增量成本为14,077英镑,每QALY的增量成本为8579英镑。

结论

对于适合开放修复的健康患者,EVAR不太可能处于新技术普遍接受的成本效益范围内。对于那些不适合传统开放修复的患者,它可能是一种比非手术治疗更具成本效益的替代方案。敏感性分析表明,研究工作应集中在确定晚期并发症和再次干预的准确发生率,特别是在手术风险高的患者中。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验